- AU$55.38bn
- AU$72.46bn
- $15.56bn
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX
Moderna's mRNA flu vaccine backed by FDA advisers (updated)
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
Factbox: Global drugmakers invest billions to boost US presence
Brief: UK'S MHRA Grants Marketing Authorisation For AUJEMFLU To Protect Adults Over 50 Against Flu
Morningstar maintains fair value for CSL despite underperformance
Australia's CSL falls on Jefferies downgrade to "hold"
Brief: Australia's Therapeutic Goods Administration Says Seqirus To Discontinue Benpen Injection Products
CSL's Seqirus to discontinue bacterial infection drug amid generic competition (updated)
Australia says CSL unit Seqirus to discontinue Benpen injections from November
Australia's CSL on track for worst week in 8 months on forecast cut, impairments
Citi turns neutral on Australia's CSL on growth uncertainty, execution risks
Brief: PAHO Signs Agreement To Reserve Pandemic Influenza Vaccine Supply For LatAm & Caribbean
Australian health stocks extend decline in CSL-led rout
CSL slips 6% as Citi slashes target price, Morningstar urges firm to hire new CEO
Morningstar trims outlook for Australia's CSL, urges firm to hire new CEO